Janux Therapeutics Stock Investor Sentiment

JANX Stock  USD 32.89  0.88  2.75%   
Slightly above 66% of Janux Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Janux Therapeutics suggests that many traders are alarmed. Janux Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Janux Therapeutics' earnings reports, geopolitical events, and overall market trends.

Comfort Level 34

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Janux Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Janux Therapeutics.

Janux Historical Sentiment

Although Janux Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Janux, such as negative comments on social media and news outlets, may cause fear in the market and push Janux Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Janux.
  

Janux Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Janux Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Janux Therapeutics Historical Investor Sentiment

Investor biases related to Janux Therapeutics' public news can be used to forecast risks associated with an investment in Janux. The trend in average sentiment can be used to explain how an investor holding Janux can time the market purely based on public headlines and social activities around Janux Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Janux Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Janux Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Janux Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Janux Therapeutics.

Janux Therapeutics Maximum Pain Price Across May 16th 2025 Option Contracts

Janux Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Janux Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Janux Therapeutics' options.
over six months ago at www.macroaxis.com         
Acquisition by Ra Capital Management, L.p. of 1397849 shares of Janux Therapeutics at 0.001 subject ...
Macroaxis News
over six months ago at thelincolnianonline.com         
Janux Therapeutics Trading Up 11.6
news
over six months ago at finance.yahoo.com         
After Soaring 222 percent in 1 Day, Is Janux Therapeutics Stock a Buy?
Yahoo News
over six months ago at fool.com         
After Soaring 222 percent in 1 Day, Is Janux Therapeutics Stock a Buy?
fool News
over a year ago at zacks.com         
Recent Price Trend in Janux Therapeutics, Inc. is Your Friend, Heres Why
zacks News
over a year ago at finance.yahoo.com         
Recent Price Trend in Janux Therapeutics, Inc. is Your Friend, Heres Why
Yahoo News
over a year ago at thelincolnianonline.com         
Wedbush Boosts Janux Therapeutics Price Target to 53.00
news
over a year ago at thelincolnianonline.com         
Acquisition by Capps Vickie L of 1493 shares of Janux Therapeutics subject to Rule 16b-3
news
over a year ago at seekingalpha.com         
Janux Therapeutics prices stock and warrants offering to raise 296.5M
seekingalpha News
over a year ago at thelincolnianonline.com         
Janux Therapeutics, Inc. Forecasted to Earn Q1 2024 Earnings of Per Share
news
over a year ago at businesswire.com         
Janux Therapeutics Announces Pricing of 296.5 Million Underwritten Public Offering of Common Stock a...
businesswire News
over a year ago at businesswire.com         
Janux Therapeutics Announces Pricing of 296.5 Million Underwritten Public Offering of Common Stock a...
businesswire News
over a year ago at businesswire.com         
Janux Therapeutics Announces Pricing of 296.5 Million Underwritten Public Offering of Common Stock a...
businesswire News
over a year ago at thelincolnianonline.com         
Brokers Set Expectations for Janux Therapeutics, Inc.s FY2027 Earnings
news
over a year ago at finance.yahoo.com         
Janux Therapeutics Announces Pricing of 296.5 Million Underwritten Public Offering of Common Stock a...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Janux Therapeutics that are available to investors today. That information is available publicly through Janux media outlets and privately through word of mouth or via Janux internal channels. However, regardless of the origin, that massive amount of Janux data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Janux Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Janux Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Janux Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Janux Therapeutics alpha.

Janux Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Janux Rockets 41 percent in Five Days as Cancer Breakthrough Fuels Market Buzz
12/03/2024
2
BTIG Research Issues Positive Forecast for Janux Therapeutics Stock Price
12/06/2024
3
Acquisition by Meyer Andrew Hollman of 9880 shares of Janux Therapeutics at 20.24 subject to Rule 16b-3
12/19/2024
4
Disposition of 25000 shares by David Campbell of Janux Therapeutics at 56.1922 subject to Rule 16b-3
12/24/2024
5
Insider Trading
12/31/2024
6
Acquisition by Meyer Andrew Hollman of 63000 shares of Janux Therapeutics at 53.24 subject to Rule 16b-3
01/02/2025
7
Disposition of 3444 shares by Meyer Andrew Hollman of Janux Therapeutics at 55.7587 subject to Rule 16b-3
01/08/2025
8
Disposition of 5768 shares by Meyer Andrew Hollman of Janux Therapeutics at 54.5111 subject to Rule 16b-3
01/14/2025
9
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
01/24/2025
10
Disposition of 100 shares by Meyer Andrew Hollman of Janux Therapeutics at 43.6 subject to Rule 16b-3
02/03/2025
11
Acquisition by Meyer Andrew Hollman of 3334 shares of Janux Therapeutics at 4.21 subject to Rule 16b-3
02/05/2025
12
Disposition of 40803 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 47.77 subject to Rule 16b-3
02/07/2025
13
Acquisition by Avalon Ventures Xi, L.p. of 1407 shares of Janux Therapeutics at .8 subject to Rule 16b-3
02/14/2025
14
Janux Therapeutics, Inc. Among the Oversold Biotech Stocks to Buy Now
02/24/2025
15
Acquisition by Avalon Ventures Xi, L.p. of 2070 shares of Janux Therapeutics at 13.22 subject to Rule 16b-3
02/26/2025
16
Janux Therapeutics GAAP EPS of -0.36 beats by 0.07
02/27/2025

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.